JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on Merck KGaA (FRA:MRK) in a report issued on Wednesday, January 10th. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other research analysts have also recently commented on the company. Oddo Bhf set a €125.00 ($154.32) price target on Merck KGaA and gave the stock a buy rating in a report on Friday, September 29th. Warburg Research set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a buy rating in a report on Monday, October 2nd. Kepler Capital Markets set a €119.00 ($146.91) price target on Merck KGaA and gave the stock a buy rating in a report on Thursday, September 21st. Commerzbank set a €109.00 ($134.57) price target on Merck KGaA and gave the stock a neutral rating in a report on Friday, September 29th. Finally, Citigroup set a €123.00 ($151.85) price objective on Merck KGaA and gave the stock a buy rating in a report on Monday, October 2nd. Twelve investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of €107.57 ($132.80).
Merck KGaA (FRA:MRK) traded down €1.06 ($1.31) during trading on Wednesday, hitting €84.90 ($104.81). The company’s stock had a trading volume of 4,699 shares. The company has a market cap of $10,950.00 and a P/E ratio of 19.88. Merck KGaA has a 1-year low of €84.90 ($104.81) and a 1-year high of €115.00 ($141.98).
TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Analysts Give Merck KGaA (MRK) a €95.00 Price Target” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/05/merck-kgaa-mrk-given-a-95-00-price-target-at-jpmorgan-chase-co.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.